# US 9,750,762 B2 · Use of yeast flakes for treating and/or preventing hyperinsulinemia > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,750,762 B2 - Document ID: US9750762B2 - Status: Granted - Kind: B2 - Application number: 12/670,436 - Filed: 2008-07-25 - Published: 2010-08-05 - Granted: 2017-09-05 - Earliest claimed: 2007-07-25 - Assignees: Lesaffre Et Compagnie - Applicants: Martine Laville; Julie-Anne Nazare; Eric Oriol - Inventors: Martine Laville; Julie-Anne Nazare; Eric Oriol - Web page: https://patentgrep.com/patent/US9750762B2 ## CPC - A61K 31/716: Glucans - A61K 31/736: Glucomannans or galactomannans, e.g. locust bean gum, guar gum - A61K 36/064: Saccharomycetales, e.g. baker's yeast - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/04: Anorexiants; Antiobesity agents - A61P 3/06: Antihyperlipidemics - A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48) - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to the use of yeast flakes for preparing a pharmaceutical composition for treating and/or preventing hyperinsulinemia. ## Claims ### Claim 1 A method of treatment of hyperinsulinemia in a patient in need thereof, comprising administering an effective amount of yeast cell walls to a non-hyperglycemic patient in need thereof, wherein said yeast cell walls have: a.) a total content of glucan and mannan of at least 34.0% dry matter content by weight; and b.) a glycogen content of less than 10.0% dry matter content by weight, wherein the non-hyperglycemic patient is overweight. ### Claim 2 (depends on 1) The method of claim 1, wherein the yeast cell walls obtained from Saccharomyces cerevisiae. ### Claim 3 (depends on 1) The method of claim 1, wherein said yeast cell walls have a total content of glucan and mannan of at least 40% dry matter content by weight. ### Claim 4 (depends on 1) The method of claim 1, wherein said yeast cell walls have a mannan content of less than 30% dry matter content by weight. ### Claim 5 (depends on 1) The method of claim 1, wherein said yeast cell walls have a mannan content of less than 2% dry matter content by weight. ### Claim 6 (depends on 1) The method of claim 1, wherein said yeast cell walls have a total content of glucan and mannan of 90% or less dry matter content by weight. ### Claim 7 (depends on 1) The method of claim 1, wherein said yeast cell walls have a total content of glucan and mannan of 45% to 90% dry matter content by weight. ### Claim 8 (depends on 1) The method of claim 1, wherein said yeast cell walls have a glycogen content of less than 8% dry matter content by weight. ### Claim 9 (depends on 1) The method of claim 1, wherein the yeast cell walls have a dry matter content of 90% or more dry matter content by weight. ### Claim 10 (depends on 1) The method of claim 1, wherein said yeast cell walls have a total content of glucan and mannan of at least 45% dry matter content by weight. ### Claim 11 (depends on 1) The method of claim 1, wherein said yeast cell walls have a mannan content less than 1% dry matter content by weight. ### Claim 12 (depends on 1) The method of claim 1, wherein the yeast cell walls have a total content of glucan and mannan equal to or less than 80% dry matter content by weight. ### Claim 13 (depends on 1) The method of claim 1, wherein the yeast cell walls have a total content of glucan and mannan of 52% to 80% dry matter content by weight. ### Claim 14 (depends on 1) The method of claim 1, wherein the yeast cell walls have a glycogen content of less than 5% dry matter content by weight. ### Claim 15 (depends on 1) The method of claim 1, wherein the yeast cell walls have a dry matter content of 94% or more. ### Claim 16 (depends on 1) The method of claim 1, wherein said yeast cell walls are obtained by: i.) submitting an aqueous suspension of yeast cells having a dry matter content between 12% and 18% by weight to hydrolysis using endogenous enzymes of said yeast cells and, optionally proteases exogenous to said yeast cells to provide an insoluble fraction; ii.) separating the insoluble fraction; and iii.) drying the separated insoluble fraction to obtain the said yeast cell walls, wherein the cells walls have a dry matter content of 90% by weight. ### Claim 17 (depends on 16) The method of claim 16, wherein hydrolysis is conducted at a temperature of between 45° C. and 55° C. for 18 to 36 hours so as to solubilise at least 60% by weight of the dry matter of said yeast cells. ### Claim 18 (depends on 16) The method of claim 16, wherein the drying step iii.) is performed by spray drying or drying on heated rolls. ### Claim 19 (depends on 16) The method of claim 16, wherein the method further comprising: iv.) heating the aqueous suspension of yeast cell walls of step i.) in an alkaline medium at a temperature of between 70° C. and 100° C. for no more than 3 hours; and v.) separating the insoluble fraction produced to obtain the yeast cell walls, wherein said yeast cell walls are β-glucan-enriched; and, and optionally: vi.) submitting the separated insoluble fraction of step ii.) to acid treatment; and vii.) collecting the insoluble fraction produced by acid treatment to obtain the yeast cell walls, wherein said yeast cell walls are β-glucan-enriched and devoid of mannans. ### Claim 20 (depends on 19) The method of claim 19, wherein the suspension of yeast cell walls is heated at 85° C. for 2 hours in an alkaline sodium hydroxide aqueous medium. ### Claim 21 (depends on 19) The method of claim 19, wherein the insoluble fraction produced by acid treatment is separated by centrifugation and washing, and optionally dried.